Medibase
EN VI JA

Medicines

Pricing

Drug-price declaration, winning tender prices, and the price-management framework under the 2023 Price Law and the 2024 Pharmacy Law amendment.

Overview

This section is a Vietnam-focused reference for drug-price management, declaration regimes, and the relationship between declared prices, tender prices, and reimbursement.

Scope:

  • Declared wholesale price (giá bán buôn thuốc dự kiến) — the new regime under the amended Pharmacy Law, declared to the Drug Administration of Vietnam (DAV).
  • Essential-medicines price declaration under the 2023 Price Law and Decree 85/2024/NĐ-CP — managed by the Ministry of Health, with the eligible list set out in Circular 28/2024/TT-BYT.
  • Winning tender prices (giá trúng thầu) — published by DAV and Vietnam Social Security; cross-reference with public-procurement rules under Circular 40/2025/TT-BYT (see Tendering & Market Access).
  • Price negotiation route (đàm phán giá) — for selected high-cost or sole-source medicines; list under Circular 05/2024/TT-BYT (as amended by Circular 37/2025/TT-BYT).
  • Public price-search portals operated by DAV and the Ministry of Health transparency portal (Cổng công khai y tế).

Important: as of 1 July 2024, the drug-pricing provisions of Decree 54/2017/NĐ-CP were repealed and replaced by the 2023 Price Law framework. The amended Pharmacy Law (44/2024/QH15, effective 1 July 2025) then introduced the new declared-wholesale-price regime, which runs in parallel with the Price Law's essential-medicines declaration. The two regimes use different lists and different declarants.

Key documents

Price Law framework:

  • Price Law No. 16/2023/QH15 — passed 19 June 2023, effective 1 July 2024. Replaces the 2012 Price Law (11/2012/QH13). Essential medicines used at healthcare facilities are listed in Section 9, Appendix I.
  • Decree 85/2024/NĐ-CP — implements the Price Law, including drug price declaration procedures. Appendix V sets out the essential medicines requiring price declaration.
  • Circular 28/2024/TT-BYT — principles and criteria for building the list of medicines required to declare prices; sets out economic and technical features and announces the list.
  • Official Dispatch 4448/BYT-QLD (1 August 2024) — DAV implementation guidance for drug price declaration under the 2023 Price Law.

Pharmacy Law framework (parallel regime):

  • Law on Pharmacy 105/2016/QH13 (Articles 107–114) — original price-management provisions.
  • Law 44/2024/QH15 (effective 1 July 2025) — introduces declared wholesale drug price (giá bán buôn thuốc dự kiến); declarants are drug importers, manufacturers, and contract manufacturers; declaration goes to DAV.

Price negotiation:

  • Circular 05/2024/TT-BYT (14 May 2024) — list of drugs, medical devices, and test equipment procured through price negotiation, and supplier-selection procedures for price-negotiation packages.
  • Circular 37/2025/TT-BYT — amends and supplements Circular 05/2024/TT-BYT.

Tender pricing (cross-reference):

  • Circular 40/2025/TT-BYT — drug bidding at public medical facilities (see Tendering & Market Access).

Repealed:

  • Decree 54/2017/NĐ-CP — drug-pricing provisions repealed effective 1 July 2024; other provisions of the decree remain in force for non-pricing matters.

Source documents

Direct links to the official text on government portals.

Primary law:

Decree:

Operational portals:

Medibase cross-references:

  • Tender — /medicine/tendering/
  • Registration process — /medicine/registration/

Recent updates

2025 — New declared wholesale price regime: Effective 1 July 2025 under Law 44/2024/QH15, drug importers, manufacturers, and contract manufacturers must declare a "giá bán buôn thuốc dự kiến" (intended wholesale price) to DAV before circulation and re-declare on change. This regime runs in parallel with — and distinct from — the Price Law's essential-medicines declaration.

2025 — Price negotiation list amended: Circular 37/2025/TT-BYT amended Circular 05/2024/TT-BYT, updating the list of medicines and supplies subject to price negotiation and refining supplier-selection procedures.

2024 — Price Law regime in force: On 1 July 2024, the Price Law 16/2023/QH15 took effect together with Decree 85/2024/NĐ-CP. The drug-pricing provisions of Decree 54/2017/NĐ-CP were repealed. Circular 28/2024/TT-BYT and DAV Dispatch 4448/BYT-QLD set out the transitional implementation for medicines required to declare prices.

2024 — Price-negotiation framework consolidated: Circular 05/2024/TT-BYT (14 May 2024) consolidated the rules and lists for price-negotiation procurement, replacing fragmented earlier guidance.

Resources & links

Public price-search portals:

Government & regulator:

  • Drug Administration of Vietnam (DAV) — https://dav.gov.vn — price-declaration guidance, notices on prices deemed unreasonable, and form templates.
  • Ministry of Health (MOH) — https://moh.gov.vn.
  • Ministry of Finance — guidance on the Price Law and its decrees.

Reference & official text:

Legal basis

See the full legal register →

Page changelog

2026-06-28: Trust-infrastructure retrofit. Reflects the 2023 Price Law, the 2024 Pharmacy Law amendment (Law 44/2024/QH15 Article 107), and Decree 163/2025/NĐ-CP Chapter VIII which replaced the Decree 54/2017 pricing provisions repealed 1 July 2024.

Effective from:
2024-07-01
Last reviewed:
2026-06-28
Page updated:
2026-08-16

Related topics — Medicines

Regulatory Affairs

Authorization, registration, and post-market obligations under the Drug Administration of Vietnam (DAV).

Drug Registration Process in Vietnam

End-to-end analysis of marketing-authorisation (giấy đăng ký lưu hành) workflow at the Drug Administration of Vietnam (DAV) — legal basis, dossier requirements, evaluation steps, statutory vs real-world timelines, and practical pitfalls under the amended Pharmacy Law (44/2024/QH15, in force 1 July 2025) and Circular 12/2025/TT-BYT.

Pharmacovigilance

Adverse drug reaction reporting, vaccine-safety surveillance, and risk management under the Drug Administration of Vietnam and the National DI & ADR Centre.

Pharmaceutical Distribution & Retail in Vietnam

Licensing for wholesalers, community pharmacies, drug shops, commune health-station drug cabinets, and traditional-medicine retailers under the post-1 July 2025 framework — the Pharmacy Business Eligibility Certificate (GCN đủ điều kiện kinh doanh dược), Good Distribution Practice (GDP), Good Pharmacy Practice (GPP), and Good Storage Practice (GSP), as reshaped by amended Pharmacy Law 44/2024/QH15 and Decree 163/2025/NĐ-CP.

Drug Import & Export in Vietnam

Two regimes — ordinary commercial trade in drugs with valid marketing authorisation, and the special import-export of drugs without registration number — under Pharmacy Law Article 60 and new Article 53a (added by Law 44/2024/QH15), Decree 163/2025/NĐ-CP Chapter IV, the Customs Law 54/2014/QH13, and the 1961 Hague Apostille Convention from 11 September 2026.

Clinical Trials & Bioequivalence in Vietnam

Authorisation, GCP, ethics review and BE-study requirements under Pharmacy Law Chapter XI as implemented by Decree 163/2025/NĐ-CP Article 23, the new Circular 50/2025/TT-BYT (effective 27 February 2026; replaces Circular 29/2018/TT-BYT, Article 9 of Circular 10/2020/TT-BYT, and Circular 08/2014/TT-BYT), Circular 43/2024/TT-BYT on ethics committees, and Circular 07/2022/TT-BYT on the BE-required substance list.

Related news — Medicine

Back to Medicines

Reference information only; not legal or medical advice.